
Catherine Tomaro-Duchesneau

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/388256/publications.pdf Version: 2024-02-01



CATHERINE

#	Article	IF	CITATIONS
1	Microencapsulated <i>Bifidobacterium longum</i> subsp. <i>infantis</i> ATCC 15697 Favorably Modulates Gut Microbiota and Reduces Circulating Endotoxins in F344 Rats. BioMed Research International, 2014, 2014, 1-11.	0.9	2,927
2	Polymeric nanohybrids and functionalized carbon nanotubes as drug delivery carriers for cancer therapy. Advanced Drug Delivery Reviews, 2011, 63, 1340-1351.	6.6	226
3	Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics: Targets and Therapy, 2011, 5, 71.	3.0	181
4	Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials, 2013, 34, 1270-1280.	5.7	161
5	Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications. Expert Opinion on Biological Therapy, 2013, 13, 631-642.	1.4	140
6	Effect of Probiotics Lactobacillus and Bifidobacterium on Gut-Derived Lipopolysaccharides and Inflammatory Cytokines: An In Vitro Study Using a Human Colonic Microbiota Model. Journal of Microbiology and Biotechnology, 2013, 23, 518-526.	0.9	129
7	Probiotics in colorectal cancer (CRC) with emphasis on mechanisms of action and current perspectives. Journal of Medical Microbiology, 2013, 62, 1107-1123.	0.7	118
8	Cholesterol Assimilation by <i>Lactobacillus</i> Probiotic Bacteria: An <i>In Vitro</i> Investigation. BioMed Research International, 2014, 2014, 1-9.	0.9	103
9	The Gut Microbiota and Human Health with an Emphasis on the Use of Microencapsulated Bacterial Cells. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-12.	3.0	71
10	A novel method for synthesizing PEGylated chitosan nanoparticles: strategy, preparation, and in vitro analysis. International Journal of Nanomedicine, 2011, 6, 485.	3.3	61
11	Development and characterization of chitosan-PEG-TAT nanoparticles for the intracellular delivery of siRNA. International Journal of Nanomedicine, 2013, 8, 2041.	3.3	60
12	Human Intestinal Enteroids With Inducible Neurogenin-3 Expression as a Novel Model of Gut Hormone Secretion. Cellular and Molecular Gastroenterology and Hepatology, 2019, 8, 209-229.	2.3	60
13	Effect of orally administered L. fermentum NCIMB 5221 on markers of metabolic syndrome: an in vivo analysis using ZDF rats. Applied Microbiology and Biotechnology, 2014, 98, 115-126.	1.7	57
14	Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization. Pharmaceuticals, 2012, 5, 236-248.	1.7	53
15	The gut microbiome, probiotics, bile acids axis, and human health. Trends in Microbiology, 2014, 22, 306-308.	3.5	53
16	Probiotics as oral health biotherapeutics . Expert Opinion on Biological Therapy, 2012, 12, 1207-1220.	1.4	48
17	Microencapsulation for the Therapeutic Delivery of Drugs, Live Mammalian and Bacterial Cells, and Other Biopharmaceutics: Current Status and Future Directions. Journal of Pharmaceutics, 2013, 2013, 1-19.	4.6	40
18	Oral Probiotic Microcapsule Formulation Ameliorates Non-Alcoholic Fatty Liver Disease in Bio F1B Golden Syrian Hamsters. PLoS ONE, 2013, 8, e58394.	1.1	38

CATHERINE

#	Article	IF	CITATIONS
19	Novel probiotic dissolvable carboxymethyl cellulose films as oral health biotherapeutics: <i>in vitro</i> preparation and characterization. Expert Opinion on Drug Delivery, 2013, 10, 1471-1482.	2.4	36
20	Investigation of probiotic bacteria as dental caries and periodontal disease biotherapeutics. Beneficial Microbes, 2014, 5, 447-460.	1.0	27
21	Probiotics for the Prevention and Treatment of Allergies, with an Emphasis on Mode of Delivery and Mechanism of Action. Current Pharmaceutical Design, 2014, 20, 1025-1037.	0.9	26
22	Systemic siRNA Delivery via Peptide-Tagged Polymeric Nanoparticles, Targeting PLK1 Gene in a Mouse Xenograft Model of Colorectal Cancer. International Journal of Biomaterials, 2013, 2013, 1-13.	1.1	23
23	Transit Time Affects the Community Stability of <i>Lactobacillus</i> and <i>Bifidobacterium</i> Species in an <i>In Vitro</i> Model of Human Colonic Microbiotia. Artificial Cells, Blood Substitutes, and Biotechnology, 2011, 39, 351-356.	0.9	22
24	Discovery of a bacterial peptide as a modulator of GLP-1 and metabolic disease. Scientific Reports, 2020, 10, 4922.	1.6	22
25	Intranasal, siRNA Delivery to the Brain by TAT/MGF Tagged PEGylated Chitosan Nanoparticles. Journal of Pharmaceutics, 2013, 2013, 1-10.	4.6	20
26	Lactobacillus fermentum NCIMB 5221 and NCIMB 2797 as cholesterol-lowering probiotic biotherapeutics: in vitro analysis. Beneficial Microbes, 2015, 6, 861-869.	1.0	17
27	Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by Enterococcus faecalis Metalloprotease GelE. MSphere, 2020, 5, .	1.3	14
28	Intranasal Delivery of Chitosan–siRNA Nanoparticle Formulation to the Brain. Methods in Molecular Biology, 2014, 1141, 233-247.	0.4	12
29	Design of a novel gut bacterial adhesion model for probiotic applications. Artificial Cells, Nanomedicine and Biotechnology, 2013, 41, 116-124.	1.9	9
30	Enrichment ofBifidobacterium longumsubsp.infantisATCC 15697 within the human gut microbiota using alginate-poly-l-lysine-alginate microencapsulation oral delivery system: anin vitroanalysis using a computer-controlled dynamic human gastrointestinal model. Journal of Microencapsulation, 2014, 31, 230-238.	1.2	6
31	866: Screening of Lactobacillus reuteri strains for their short chain fatty acids production, stability and potential in colorectal cancer: In-vitro analysis. European Journal of Cancer, 2014, 50, S212.	1.3	1